Business Context and Reporting Period
Company: Duos Technologies Group, Inc. (DUOT)
Filing Type: Form 8-K (Current Report)
Date of Report: April 14, 2025
Principal Executive Offices: Jacksonville, Florida
Reporting Period: Event date of April 14, 2025
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital market transaction.
| Metric | Value |
|---|---|
| Additional Offering Capacity Authorized | $8,850,000 |
| Previous Offering Capacity (Original Agreement) | $7,500,000 |
| Securities Type | Common Stock (par value $0.001) |
| Sales Method | At-The-Market Issuance (Rule 415) |
Material Changes
On April 14, 2025, the Company entered into the First Amendment to its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The primary material change is the increase in the aggregate offering price of shares that may be sold under the agreement by $8,850,000. This amendment builds upon the Original Agreement dated May 17, 2024, which had an initial aggregate offering price of $7,500,000.
Guidance, Outlook, and Risks
- Management Commentary: The Company retains the right to set sales parameters, including the number of shares, time periods, daily limits, and minimum prices. The Agent will use commercially reasonable efforts to sell shares consistent with normal trading practices.
- Termination Rights: Both the Company and the Agent have the right to terminate the Sales Agreement in their sole discretion, subject to the terms and conditions set forth in the agreement.
- Regulatory Status: The offer and sale of shares are made pursuant to an effective shelf registration statement on Form S-3 (No. 333-272603). A prospectus supplement was filed with the SEC on April 14, 2025.
- Risks/Contingencies: The filing explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy in any state where such offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the total aggregate offering price available under the amended Sales Agreement ($16,350,000).
- Review the full text of the First Amendment (Exhibit 1.2) for specific terms regarding sales parameters and termination conditions.
- Confirm the status of the shelf registration statement (No. 333-272603) and the filed prospectus supplement.
- Monitor future filings for actual share sales executed under this agreement to assess dilution impact.